The global enteral feeding formulas market is projected to reach USD 8.2 billion by 2027 from USD 5.2 billion in 2022, growing at a CAGR of 9.5% during the forecast period. Growth in this market is largely driven by factors such as the benefits and cost-effectiveness of enteral nutrition over parenteral nutrition, rise in preterm births, growing demand for enteral feeding in the home care sector, and rapid growth in the geriatric population and subsequent growth in the prevalence of chronic diseases. On the other hand, complications involved with enteral feeding and lack of patient awareness are expected to hinder the market growth.
Abbott is the leading player in the enteral feeding formulas market. The company operates in the market through its Nutritional Products segment. With its strong global presence and wide distribution network, the company possesses a robust product portfolio comprising adult and pediatric nutritional formulas. The company focuses on developing innovative formulas and expanding its global presence.
To know about the assumptions considered for the study download the pdf brochure
Over the last two years, the company has observed an increase in the sale of its nutritional products. Excluding the impact of foreign exchange, total adult nutrition sales increased 12.8% in 2021 and 10.3% in 2020, led by the continued growth of Ensure, while pediatric nutrition sales increased 3.3% in 2021 and 0.3% in 2020, driven by the Pedialyte, PediaSure, and Similac brands in the US. The company aims to enhance its portfolio by introducing line extensions of its science‑based products.
Nestlé is a multinational health, nutrition, and wellness company. It manufactures and markets milk-based products, pharmaceuticals, baby foods and cereals, ophthalmic goods, and cooking aids. The company operates in seven major business segments—Powdered and Liquid Beverages, Petcare, Nutrition and Health Science, Prepared Dishes and Cooking Aids, Milk Products and Ice cream, Confectionary, and Water. The company provides a range of enteral feeding formulas through its Nestlé Health Science segment. In 2021, the Nestlé Health Science segment contributed the largest share of 5.5% to the company’s revenue, which was 3.9% in 2020. The continuous growth of this segment is primarily due to its strong product portfolio, brand recognition, and high demand for nutritional formulas. In 2021 and 2022, the company acquired Orgain (US) and The Bountiful Company (US), which enabled the company to expand its presence in the market. The company operates in over 186 countries across Zone EMENA (Europe, Middle East, and North Africa), Zone AMS (The Americas), and Zone AOA (Asia, Oceania, and Africa).
Fresenius Kabi has a strong global footprint and focuses on providing high-quality, innovative clinical nutrition solutions. The company has a wide geographic presence in established markets and a broad product portfolio that includes nutritional supplements and tube feed & pediatric feed products. Along with this, Fresenius Kabi supports external development projects. The company also established the United for Clinical Nutrition (UFCN) initiative to raise awareness of disease-related malnutrition worldwide. This has enabled the company to expand its geographic presence.
Danone observed increased demand for its specialized nutrition formulas in the Asia Pacific. Infant nutrition posted growth in revenue, driven by China and the Rest of the World. The company also focuses on adopting collaboration and geographic expansion to sustain its position in the market. With the recall of some nutritional formulas by Abbott in May 2022, Danone announced that it would double the shipments of Neocate formula to the US.
The company has a strong foothold in the enteral feeding formulas market. This is due to its strong sales and distribution network. The company offers a wide range of child and adult feeding formulas in the market through its Specialized Nutrition business segment. The specialized nutrition business of Danone is expected to grow through multi-channel sales strategies and the expansion of its product portfolio.
B. Braun Melsungen AG focuses on expanding its enteral feeding product portfolio. For enteral nutrition, the company offers feeding formulas and devices such as standard diets, specific diets, enteral nutrition pumps, pump administration systems, gravity administration systems, feeding tubes, and safety systems. A product portfolio enables the company to maintain its competitive position in the market. In 2021, the Healthcare business witnessed a 5.1% in revenue, with growth in North America, Germany, and Latin America markets being the major drivers, followed by Switzerland and East Europe. Additionally, Japan, Australia, and Thailand exhibited double-digit growth. The company aims to establish its market position in these countries, driven by increasing demand for enteral nutrition.
Enteral Feeding Formulas Market by Product (Polymeric, Elemental, Disease-specific), Stage (Adults, Pediatrics), Application (Oncology, Gastroenterology, Neurology, Hypermetabolism), End User (Hospitals, LTCF, Home care) - Global Forecast to 2027
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE